Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals focuses on developing and commercializing prescription products for hospital acute care, gastroenterology, and oncology. Its products include injections for treating acetaminophen poisoning, pain and fever, and certain infections. The company also develops treatments for constipation, Helicobacter pylori infection, duodenal ulcer disease, and hyponatremia. Additionally, Cumberland Pharmaceuticals is developing a treatment for rheumatoid arthritis and psoriasis, as well as a product candidate for aspirin-exacerbated respiratory disease and other conditions. The company has completed phase II clinical trials for certain products and is headquartered in Nashville, Tennessee.
Overview
Strengths
- Valued below its Drug Manufacturers - Specialty & Generic peers: P/FCF 15.8x vs. a median of 21.4x.
- Skin in the game: insiders own 42% of the shares, aligning management with shareholders.
- Improving fundamentals over the last year: return on assets up 4.9 points, gross margin up 2.4 points and asset turnover up 15.7%.
- Cheaper than its own history: P/FCF 15.8x vs. a historical average of 24.1x.
- Paying down debt: long-term debt fell by 6.6 percentage points of total assets last year.
Weaknesses
- Operating profit does not cover interest expense.
- Our discounted cash flow model finds no value to support the current price: operating profit does not cover interest expense.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unstable profitability: operating margin ranged from -24% to -6% over the last 6 years, with operating losses in 6 of them.
- Valued at a premium to its Drug Manufacturers - Specialty & Generic peers: EV/EBITDA 24.8x vs. a median of 12.5x.
- Small company (enterprise value $74 million): thinner analyst coverage, lower liquidity and wider valuation uncertainty.
Key Financial Data